TCM
MRTX

Tygh Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Tygh Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,369
Closed -$3.61M – 105
2021
Q2 		$3.61M Sell
22,369
-236
-1% -$37.9K 0.49% 75
2021
Q1 		$3.87M Buy
22,605
+878
+4% +$174K 0.55% 73
2020
Q4 		$4.77M Sell
21,727
-150
-0.7% -$32.4K 0.74% 64
2020
Q3 		$3.63M Buy
+21,877
New +$2.99M 0.69% 62

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tygh Capital Management's MRTX Position: Q3 2021 in Review

Tygh Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 22,369 shares — an estimated $3.61M sold.

Tygh Capital Management first reported a position in MRTX in Q3 2020 and held it in 4 quarters. The position peaked at $4.77M in Q4 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

  • Tygh Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Tygh Capital Management sold 22,369 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $3.61M.
  • Tygh Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • Tygh Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $4.77M in Q4 2020.
  • 238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Tygh Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.